Hepion Pharmaceuticals In...

NASDAQ: HEPA · Real-Time Price · USD
0.04
-0.00 (-3.15%)
At close: Jun 05, 2025, 3:49 PM

Company Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms.

The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.

Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc. logo
Country United States
IPO Date Feb 10, 2014
Industry Biotechnology
Sector Healthcare
Employees 22
CEO John Patrick Brancaccio CPA

Contact Details

Address:
399 Thornall Street
Edison, New Jersey
United States
Website https://www.hepionpharma.com

Stock Details

Ticker Symbol HEPA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001583771
CUSIP Number 426897401
ISIN Number US4268974015
Employer ID 46-2783806
SIC Code 2834

Key Executives

Name Position
John Patrick Brancaccio CPA Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board
Sharen Pyatetskaya Director of Investor Relations

Latest SEC Filings

Date Type Title
May 30, 2025 8-K Current Report
May 19, 2025 10-Q Quarterly Report
May 15, 2025 SCHEDULE 13G Filing
May 15, 2025 NT 10-Q Filing
May 12, 2025 8-K Current Report
May 06, 2025 8-K Current Report
Apr 29, 2025 ARS Filing
Apr 28, 2025 DEF 14A Filing
Apr 23, 2025 PRER14A Filing
Apr 17, 2025 8-K Current Report